This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
CanadaBis Capital Unveils New 60%+ Double-Infused Pre-Roll Under Dab Bods Brand; Says "Setting New Standard" For THC Potency In Canada Market MT
CanadaBis Capital, With Sub Stigma Grow, Fiscal Q2 2024 Net Revs Down On Prior Quarter; CANB Down Near 40%, Hit Fresh 52 Week Lows; Separately Confirms No Material Change MT
CanadaBis Capital Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 CI
CanadaBis Capital's Fiscal Q1 Profit, Revenue Grows MT
CanadaBis Capital Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023 CI
CanadaBis Capital's Fiscal Q4 Profit, Revenue Rises; Up 5% MT
CanadaBis Capital's Fiscal Q4 Profit, Revenue Rises MT
CanadaBis Capital Inc. Reports Earnings Results for the Full Year Ended July 31, 2023 CI
CanadaBis Capital CFO Steps Down, Replacement Appointed MT
CanadaBis Capital Inc. Announces Appointment of Garfield Richards as Chief Financial Officer CI
CanadaBis Capital's Fiscal Q3 Profit, Net Revenue Grows; Provides Outlook; Up 10.7% MT
CanadaBis Capital's Fiscal Q3 Profit, Net Revenue Grows; Provides Outlook MT
CanadaBis Capital Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023 CI
Canadabis Capital Inc. Launches New Super Slim Style Pre Roll Line CI
Canadabis Capital Appoints Nicole Bacsalmasi Ll.B to the Board CI
CanadaBis Capital Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023 CI
CanadaBis Capital Says Intends to Introduce More Products in 2023, Expects Sales Growth to Continue MT
CanadaBis Capital Swings to Q1 Net Income from Year-Ago Loss; Net Revenue $5.15 Million Vs $1.85 Million MT
CanadaBis Capital Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022 CI
CanadaBis Capital Inc. Reports Earnings Results for the Full Year Ended July 31, 2022 CI
CanadaBis Capital Inc. Auditor Raises 'Going Concern' Doubt CI
CanadaBis Capital Swings to Q3 Net Income from Year-Ago Loss; Revenue Rises MT
CanadaBis Capital Inc. Provides Sales Guidance for the Next Quarter CI
CanadaBis Capital Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2022 CI
CanadaBis Capital Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2022 CI
Chart CanadaBis Capital Inc.
More charts
CanadaBis Capital Inc. is a vertically integrated Canadian cannabis company. The Company’s principal business is the production and sale of recreational cannabis and cannabis extracts. The Company operates through three segments: Cultivation and wholesale, Retail and Extract. The Cultivation and wholesale segment is engaged in cultivating and distributing cannabis and cannabis products to and through, provincial liquor and cannabis boards, which are subsequently sold to end consumers. Its Retail segment is involved in the sale of cannabis and cannabis related products to end consumers on premise owned and operated by the Company. Its Extract segment provides cannabinoid extraction services for the Company and also to other licensed producers. The Company’s subsidiaries include Stigma Pharmaceuticals Inc., 1998643 Alberta Ltd., Full Spectrum Labs Ltd., 2103157 Alberta Ltd., and Goldstream Cannabis Inc.
More about the company
  1. Stock Market
  2. Equities
  3. CANB Stock
  4. News CanadaBis Capital Inc.
  5. CanadaBis Capital's Fiscal Q3 Profit, Net Revenue Grows; Provides Outlook